Insider Mike Doustdar to lead Novo Nordisk

Mike Doustdar will succeed Lars Fruergaard Jørgensen as president and CEO of Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO), taking the helm of the world’s second-largest obesity company as an insider with experience in operations and finance.

Jørgensen, who announced in May that he would step aside from the Danish company’s top job, led Novo Nordisk’s evolution into a dominant player in obesity during an eight-year tenure in which the company’s sales, profits and stock all nearly tripled...